Dr. Lee brings over 16 years of oncology drug development experience spanning early-stage discovery to translational research in both biotech and pharmaceutical settings. He is the Executive Director of Cancer Biology at Riva Therapeutics. Prior to Riva, he spent over 12 years with increasing responsibilities at Pfizer and served as project co-lead for several cell cycle programs, as well as establishing HTS platforms to inform responder patient stratification and identify therapeutic combinations for late-stage candidate programs. In addition, he contributed to the development of 3 FDA approved drugs at Pfizer (Ibrance, Xalkori, and Lorbrena). Subsequent to that, he helped build and lead a multidisciplinary team of cancer biologists to support discovery programs and translational research to expand clinical indications at Turning Point Therapeutics.
Dr. Lee received a B.S. in Cell Biology from the University of California, San Diego and a Ph.D. in Molecular Cell and Development Biology from the University of California, Los Angeles.